What is a Clinical Performance Report (CPR)?

Clinical Performance, as defined in Article 2(41) of IVDR 2017/746, refers to a device’s ability to yield results that correspond with specific clinical conditions or physiological/pathological processes, as well as its suitability for the intended user and target population. Once Analytical Performance has been established, manufacturers are required to conduct Clinical Performance studies. These studies aim to verify and substantiate elements of the device’s performance that cannot be fully assessed through laboratory testing, literature data, or routine diagnostic applications. This underscores the importance of evaluating how the device functions in real-world clinical settings.

Under the EU In Vitro Diagnostic Medical Device Regulation (IVDR) [Regulation (EU) 2017/746], the CPR is an integral part of the broader Performance Evaluation Report (PER). It compiles data from clinical performance studies, scientific literature, and real-world evidence to confirm that the device functions as intended in a clinical setting.

 Reference: Article 2(41), Article 56(1), Annex XIII Part A Section 1.3.2

Purpose of the CPR

The CPR plays a critical role in:

• Demonstrating clinical evidence that supports the claimed performance of the IVD device.

• Validating the intended use through measurable outcomes like sensitivity, specificity, predictive values,negative predictive value and likelihood ratios expected values in normal and affected populations.

• Supporting regulatory submissions, showing that the device meets the General Safety and Performance Requirements (GSPRs) under Annex I of the IVDR.

• The CPR also serves as the clinical justification that helps authorities assess whether the device provides sufficient benefit in relation to any associated risks.

 Reference: Article 56(1), Annex I, Annex XIII Part A Section 1.3.2

Why is a Clinical Performance Report (CPR) Mandatory under IVDR?

The In Vitro Diagnostic Regulation (IVDR) introduced stricter requirements to ensure that IVD devices placed on the EU market are both safe and clinically reliable. A Clinical Performance Report (CPR) is central to this framework, as it provides documented evidence that a device performs as claimed in its intended clinical context.

Reference: Article 5(3), Article 56(1), Annex XIII

Focus on Safety, Performance, and Scientific Validity

The CPR is designed to show that:

• The device consistently delivers accurate and reliable results, reducing the risk of incorrect diagnoses.

• Its intended medical purpose is scientifically justified, linking the analyte or biomarker with a specific clinical condition.

• The evidence supporting the device is not only analytically strong but also clinically meaningful, ensuring that results improve patient care and outcomes.

This ensures that every claim made by the manufacturer is backed by scientifically valid and clinically tested data.

Reference: Article 56(1), MDCG 2022-2

Difference from the Legacy IVDD Approach

Under the older In Vitro Diagnostic Directive 98/79/EC (IVDD), manufacturers had more flexibility and, in many cases, limited obligations to provide robust clinical evidence. Many devices could reach the market with minimal clinical performance data, especially low and medium-risk products.

With the IVDR, the bar has been raised significantly:

• The CPR is now a mandatory component of the performance evaluation process.

• Manufacturers must integrate data from clinical performance studies, scientific literature, and post-market evidence.

• The CPR must be continuously updated to reflect new data from Post-Market Performance Follow-up (PMPF), ensuring ongoing safety and effectiveness throughout the device’s lifecycle.

Reference: Article 56(1), Annex XIII, MDCG 2022-2

This shift reflects the EU’s commitment to improving patient safety, data reliability, and regulatory transparency.

What Must a Clinical Performance Report (CPR) Contain?

A Clinical Performance Report (CPR) under the IVDR is not just a summary document, it is the core evidence showing that an IVD device delivers clinically valid and reliable results. To meet regulatory expectations, the CPR should include the following key components:

1. Summary of Clinical Performance Studies

The CPR must provide a clear overview of clinical studies conducted with the device. This includes:

• Study objectives, design, and methodology

• Characteristics of the study population

• Testing procedures and endpoints

• Outcomes that demonstrate how the device performs in real clinical use

This section ensures transparency in how data was gathered and validates that the device was tested under conditions reflecting its intended use.

 2. Scientific Validity and Analytical Performance

A strong CPR must also demonstrate that:

• The scientific basis of the biomarker or analyte being tested is well-established and linked to a specific clinical condition.

• The analytical performance of the device (such as accuracy, precision, reproducibility, detection limits, and interference testing) supports its intended purpose.

Together, these elements confirm that the device has both a valid scientific foundation and the technical capability to deliver dependable results.

 3. Statistical Analysis and Data Interpretation

The data presented in the CPR must be supported by robust statistical evaluation. This typically includes:

• Measures of clinical sensitivity, specificity, and predictive values

• Confidence intervals and error margins

• Comparative analysis with existing diagnostic methods

• Justification of acceptance criteria and thresholds

Proper interpretation of these results ensures that the device’s claims are not only supported by evidence but also withstand regulatory scrutiny.

Reference: Annex XIII Part A Sections 1.2 and 1.3.2

How is the CPR Related to the Performance Evaluation Plan (PEP) and Performance Evaluation Report (PER)?

The Clinical Performance Report (CPR) is not a stand-alone document it is one piece of the larger performance evaluation framework defined under the IVDR. To understand its role, it’s important to see how it connects with the Performance Evaluation Plan (PEP) and the Performance Evaluation Report (PER).

Integration within the Performance Evaluation Lifecycle

1. Performance Evaluation Plan (PEP)
   
   

   • This is the starting point.

   • It outlines how the manufacturer will collect and assess data covering scientific validity, analytical performance, and clinical performance.

   • It serves as the blueprint for generating the evidence that will later feed into the PER and CPR.
     
     

2. Performance Evaluation Report (PER)
   
   

   • This is the overarching document summarizing the entire evaluation process.

   • It consolidates all evidence gathered as per the PEP, including literature reviews, clinical studies, and post-market data.

   • Within the PER, the CPR specifically addresses the clinical performance component.
     
     

3. Clinical Performance Report (CPR)
   
   

   • A focused document that highlights the clinical dimension of performance evaluation.

   • It demonstrates, through clinical data, that the device performs safely and effectively for its intended use.

   • The CPR is an annex or integral part of the PER, ensuring that clinical evidence is distinctly visible and compliant with Annex XIII of the IVDR.

 Reference: Article 56(1), Annex XIII Part A Sections 1.2–1.3

How Often Should a Clinical Performance Report (CPR) Be Updated?

The Clinical Performance Report (CPR) is not a one-time submission. Under the IVDR framework, manufacturers are expected to treat it as a living document, updated regularly to reflect new data and ensure that the IVD device continues to meet safety and performance requirements throughout its lifecycle.

Frequency Based on Device Class

• Class C and Class D Devices
  These are high-risk IVDs, often used in critical diagnostic areas such as infectious diseases, cancer, or blood safety. For these devices, the CPR must be reviewed and updated at least once per year. This ensures that any new data or risks are promptly assessed and documented.

• Class A and Class B Devices
  Lower-risk devices may not require such frequent updates. The CPR should still be reviewed periodically, with the frequency determined by the device’s risk profile, post-market findings, and clinical relevance. While the IVDR does not mandate a strict annual update for these classes, manufacturers are expected to justify their chosen update interval in line with their PMS strategy.

 Reference: Article 10(9), Article 56(1), Annex XIII Part A Section 1.3.2, Annex III Section 1

 Link to PMS and PMPF Activities

Updates to the CPR are closely tied to Post-Market Surveillance (PMS) and Post-Market Performance Follow-up (PMPF):

• PMS data such as complaints, vigilance reports, and user feedback may highlight trends that require the CPR to be updated.

• PMPF activities generate fresh evidence on how the device performs in real-world clinical practice. This information must be integrated into the CPR to demonstrate ongoing clinical validity and performance.

• Together, PMS and PMPF ensure that the CPR remains current, evidence-driven, and aligned with the device’s intended purpose.

Reference: Article 78, Article 79, Annex III Section 1, Annex XIII Part A Section 1.3.2

Common Pitfalls in Drafting a Clinical Performance Report (CPR)

Preparing a CPR can be challenging, and many manufacturers run into avoidable mistakes that weaken the credibility of their submission. Recognizing these pitfalls early can help ensure that your report is both compliant and persuasive.

1. Lack of Robust Scientific Evidence

One of the most common issues is relying on insufficient or weak evidence. A CPR must present clear, traceable data that supports the diagnostic claims of the IVD device. Without solid scientific backing, regulatory reviewers may question the reliability of the conclusions. Evidence should be drawn from well-designed studies, peer-reviewed literature, or real-world performance data rather than general assumptions.

2. Incomplete or Superficial Literature Review

A CPR often includes a literature review to support scientific validity. However, many reports fail to establish a comprehensive and systematic search strategy. Omitting relevant studies, failing to apply clear inclusion/exclusion criteria, or relying only on a narrow set of references can create gaps in the evidence. A well-documented, methodical review is essential to show that all relevant data has been considered.

3. Poor Linkage to Intended Use

Even when strong data is presented, another frequent mistake is failing to connect the evidence directly to the device’s intended use. Performance results must clearly demonstrate that the device is fit for its stated purpose and applicable to the target patient population. If this connection is unclear or poorly explained, regulators may view the evidence as incomplete, regardless of its scientific strength.

Avoiding these pitfalls requires careful planning, structured evidence gathering, and clear presentation. A CPR that combines comprehensive data, systematic literature analysis, and strong alignment with the intended use will stand up to scrutiny and support a successful IVDR submission.

Reference: MDCG 2022-2, Annex XIII Part A Section 1.3.2

Tips for Creating a Strong Clinical Performance Report (CPR)

A well-prepared CPR can make the difference between smooth regulatory approval and prolonged back-and-forth with notified bodies. The strength of your report lies not only in the data you provide but also in how effectively it is organized and presented.

1. Use Diverse and Reliable Data Sources

Building a strong CPR starts with collecting evidence from multiple, credible sources. These may include:

• Results from clinical performance studies designed in line with IVDR requirements.

• Data from peer-reviewed literature that supports the device’s clinical claims.

• Registries or clinical databases that provide additional real-world insights.

Using varied sources strengthens your argument by showing that the device’s performance is consistently validated across different settings.

2. Incorporate Real-World Evidence (RWE)

Beyond controlled studies, regulators value real-world performance data as it reflects how the device behaves in actual clinical use. RWE can come from:

• Post-market surveillance (complaints, vigilance data, feedback from users).

• Post-market performance follow-up (PMPF) activities that capture evidence from day-to-day practice.

• Clinical use registries and large-scale data collection initiatives.

This type of evidence adds credibility by proving that the device delivers reliable results outside of trial conditions.

 3. Leverage Clinical Studies Effectively

Clinical studies form the backbone of the CPR. To maximize their impact:

• Clearly outline the study design, including objectives, sample size, and endpoints.

• Demonstrate how the results link to the device’s intended purpose.

• Use statistical analyses to highlight sensitivity, specificity, predictive values, and confidence intervals.

• Provide transparent explanations of any study limitations and how they were addressed.

By presenting studies with clarity and context, you show regulators that your evidence is not only scientifically sound but also directly applicable to patient care.

Reference: MDCG 2022-2, Article 56(1), Annex XIII

IVDR CPR Requirements vs. Other Regions: EU, India, US

CPR under IVDR vs Clinical Evidence in India’s CDSCO

• IVDR emphasizes structured CPR including scientific validity, analytical, and clinical performance.

• CDSCO (India) requires clinical evidence but allows greater reliance on foreign data if the device is already approved overseas.

Comparison to FDA expectations

• FDA requires analytical validation and often clinical validation, documented in summaries like 510(k) or PMA submissions.

• Unlike IVDR, FDA focuses more on demonstrating substantial equivalence or safety-effectiveness evidence rather than a structured CPR.

How to align global data for EU submissions

• Synchronize study protocols early to fulfill both FDA and IVDR needs.

• Collect performance data in diverse geographies to support global markets.

• Map clinical evidence to IVDR’s tripartite structure (validity, analytical, clinical).

Regulatory References

The CPR is directly referenced in the following parts of the IVDR:

• Article 56(1) – Outlines the need for a documented performance evaluation plan and report, including clinical performance aspects.

• Annex XIII, Part A, Section 1.3.2 – Specifies the structure and content required in a clinical performance study report and its integration into the overall performance evaluation.

• MDCG 2022-2 - Guidance on general principles of clinical evidence for In Vitro Diagnostic medical devices (IVDs) 

• Article 2 of Regulation (EU) 2017/745

• MDCG 2022-2: General principles of clinical evidence for IVDs

• Article 2(41): Defines clinical performance

In summary, the CPR consolidates all clinical data that confirms the real-world diagnostic value of an IVD device, ensuring transparency, traceability, and scientific rigor in compliance with the IVDR.

How We Can Help

At Morulaa HealthTech, we specialize in guiding medical device and IVD manufacturers through the complex regulatory requirements needed to successfully enter and grow in international markets. Preparing a Clinical Performance Report (CPR) is often challenging, but with our expertise, you can be assured of a structured, compliant, and efficient process.

Our Consulting Support

• End-to-End CPR Development – We help draft, review, and update Clinical Performance Reports in line with IVDR requirements.

• Gap Assessments – Our team identifies missing data or weak points in your current documentation and provides clear strategies to strengthen them.

• Lifecycle Compliance – From pre-market planning to post-market performance follow-up (PMPF), we ensure your CPR remains up to date.

• Customized Solutions – We tailor our approach to match your device type, classification, and target market.